Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bank of NT Butterfield & Son

42.31
+0.37000.88%
Volume:138.81K
Turnover:5.89M
Market Cap:1.79B
PE:8.80
High:42.79
Open:41.88
Low:41.67
Close:41.94
Loading ...

Bank of N. T. Butterfield & Son Limited Conducted Annual General Meeting

Reuters
·
22 May

Why Bank of NT Butterfield & Son (NTB) Might be Well Poised for a Surge

Zacks
·
03 May

Bank of NT Butterfield & Son (NTB) Is Up 5.07% in One Week: What You Should Know

Zacks
·
01 May

Bank of Butterfield Is Maintained at Market Perform by Keefe, Bruyette & Woods

Dow Jones
·
25 Apr

N.T. Butterfield price target raised to $48 from $44 at Keefe Bruyette

TIPRANKS
·
25 Apr

Bank of N.T. Butterfield & Son First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.
·
25 Apr

Bank of Nt Butterfield & Son Ltd : Kbw Raises Target Price to $48 From $44

THOMSON REUTERS
·
25 Apr

KBW Reaffirms Their Hold Rating on Bank of NT Butterfield & Son (NTB)

TIPRANKS
·
24 Apr

Bank of N.T. Butterfield & Son's Q1 Core Earnings, Revenue Rise

MT Newswires Live
·
24 Apr

Bank of NT Butterfield & Son Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
24 Apr

Bank of NT Butterfield & Son (NTB) Q1 Earnings and Revenues Surpass Estimates

Zacks
·
24 Apr

Bank of NT Butterfield & Son: Q1 Earnings Snapshot

Associated Press Finance
·
24 Apr

Bank of N.T Butterfield Q1 Adj. EPS $1.23 Beats $1.11 Estimate, Sales $148.20M Beat $140.89M Estimate

Benzinga
·
24 Apr

BRIEF-Bank of N T Butterfield Q1 Adjusted EPS USD 1.3

Reuters
·
24 Apr

Bank of N T Butterfield Q1 Credit Loss Allowance USD -25.3 Million

THOMSON REUTERS
·
24 Apr

Butterfield Reports First Quarter 2025 Results

Business Wire
·
24 Apr

Discovering US Undiscovered Gems in April 2025

Simply Wall St.
·
16 Apr

Press Release: Butterfield to Announce First Quarter 2025 Financial Results on April 23, 2025 and Host Earnings Conference Call on April 24, 2025

Dow Jones
·
10 Apr

Is Bank of NT Butterfield & Son Ltd. (NTB) The Best Small Cap Bank Stock To Invest In Now?

Insider Monkey
·
02 Apr

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

GlobeNewswire
·
11 Mar